Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a strong buy rating to the company.
A number of research firms have recently issued reports on RBGLY. Citigroup upgraded shares of Reckitt Benckiser Group to a "strong-buy" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. downgraded Reckitt Benckiser Group from an "overweight" rating to a "neutral" rating in a research note on Thursday, August 29th. Barclays upgraded Reckitt Benckiser Group to a "strong-buy" rating in a research report on Friday, October 4th. Sanford C. Bernstein lowered Reckitt Benckiser Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 4th. Finally, UBS Group upgraded Reckitt Benckiser Group to a "strong-buy" rating in a research note on Wednesday, September 18th.
View Our Latest Research Report on Reckitt Benckiser Group
Reckitt Benckiser Group Trading Down 1.8 %
Shares of Reckitt Benckiser Group stock traded down $0.22 during trading on Friday, reaching $12.05. The company had a trading volume of 248,244 shares, compared to its average volume of 442,616. Reckitt Benckiser Group has a fifty-two week low of $10.24 and a fifty-two week high of $15.03. The firm's fifty day moving average is $12.33 and its 200-day moving average is $11.71. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.
Reckitt Benckiser Group Company Profile
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Featured Articles
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.